

**Simeon Taylor, M.D., Ph.D.**  
**Vice President, Research and Scientific Affairs**  
**Bristol-Myers Squibb Company**

Dr. Taylor received his education at Harvard University, from which he received a B. A. in Chemistry, Ph.D. in Biological Chemistry, and an M.D. degree. He completed clinical training at Massachusetts General Hospital with a specialty in Internal Medicine and a sub-specialty in Endocrinology & Metabolism. He joined the Diabetes Branch in the Division of Intramural Research at the National Institutes of Health in 1979, where he rose to the position of Branch Chief, a position he held for eleven years (1989-2000). In addition, he served as Director of the NIH Inter-Institute Clinical Training Program in Endocrinology and Metabolism (1995-1998). During his time at NIH, Dr. Taylor's research was directed toward elucidating the molecular mechanisms of insulin action and also toward understanding the causes of insulin resistance in human diseases such as diabetes and obesity. This work resulted in more than 200 publications in the scientific literature. Dr. Taylor's contributions have been recognized by several awards, including the Outstanding Service Award of the United States Public Health Service (1990) and the American Diabetes Association's Outstanding Scientific Achievement Award ("Lilly Award") (1992). In addition, he has served on the editorial boards of numerous journals, including *The Journal of Clinical Investigation*, *The Journal of Clinical Endocrinology and Metabolism*, *The Journal of Biological Chemistry*, *Endocrinology*, *Molecular Endocrinology*, and *Endocrine Reviews*. After 21 years at National Institutes of Health, Dr. Taylor moved to Eli Lilly and Co., where he was a Lilly Research Fellow in the Department of Endocrine Research (2000-2002). In 2002, Dr. Taylor was appointed as Vice President, Discovery Biology at the Hopewell, NJ site of the Bristol-Myers Squibb Company, where he led Drug Discovery Biology in Cardiovascular and Metabolic Diseases (2002-2010). In addition, he served as Co-Chair of the CV and Metabolic Disease Strategy Team (2002-2008) and currently serves as Co-Chair of the Metabolic Disease Early Asset Team.